The specter of generic rivalry has repeatedly loomed over copyright’s famous drug, PDE5 Inhibitor, sparking questions about the outlook of related drug ventures. While first times saw impressive profits, the patent expiration has opened the door for less expensive substitutes, possibly diminishing earnings and creating a real risk for shareholder